Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company specialized in T-cell immunotherapy. The company uses its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. It is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of Epstein Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in South San Francisco, California, the US.Atara Biotherapeutics Inc Key Recent Developments
- Feb 06, 2023: Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
- Feb 03, 2023: Atara Biotherapeutics : Appointment
- Dec 19, 2022: Atara Biotherapeutics Announces Changes to Its Board of Directors
- Nov 08, 2022: Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Viracta Therapeutics Inc
- Medtronic Plc
- TG Therapeutics Inc
- Novartis AG
- EMD Serono Inc
- Tessa Therapeutics Ltd
- Sanofi
- Bristol-Myers Squibb Co
- F. Hoffmann-La Roche Ltd
- Viracta Therapeutics Inc
- TG Therapeutics Inc
- Bristol-Myers Squibb Co
- EMD Serono Inc
- Tessa Therapeutics Ltd
- Sanofi
- F. Hoffmann-La Roche Ltd
- Novartis AG